Martín-Martos F et al, Riete Investigators.Gender differences in cancer patients with acute venous thromboembolism. Thromb Res. 2015 Feb;135 Suppl 1:S12-5. PubMed PMID: 25903526.

Thromb Res. 2015 Feb;135 Suppl 1:S12-5. doi: 10.1016/S0049-3848(15)50433-7. Epub 2015 Feb 9.

Gender differences in cancer patients with acute venous thromboembolism.

Martín-Martos F(1), Trujillo-Santos J(1), Barrón M(2), Vela J(3), Javier Marchena P(4), Braester A(5), Hij A(6), Hernández-Blasco L(7), Verhamme P(8), Manuel M(9), Riete Investigators.

Author information:
(1)Department of Internal Medicine, Hospital General Universitario Santa Lucía, Murcia, Spain.
(2)Department of Pneumonology, Complejo Hospitalario San Pedro, La Rioja, Spain.
(3)Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain.
(4)Department of Internal Medicine, Parc Sanitari Sant Joan de Deu-Hospital General, Barcelona, Spain.
(5)Department of Haematology, Western Galilee Hospital, Nahariya, Israel.
(6)Internal Medicine and Vascular Diseases Unit, Hôpital Saint-Louis, Paris, France.
(7)Department of Pneumonology, Hospital General Universitario de Alicante, Alicante, Spain.
(8)Department of Cardiovascular Science, Vascular Medicine and Haemostasis, University of Leuven, Leuven, Beigium.
(9)Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Electronic address: mmonreal.germanstrias@gencat.cat.

BACKGROUND: The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender.

METHODS: We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender.

RESULTS: As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47-0.99) and death (RR: 0.90; 95% CI: 0.83-0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65-1.06) and major bleeding (RR: 0.89; 95% CI: 0.74-1.08).

CONCLUSIONS: During the course of anticoagulation, cancer women with VTE had a better outcome than men.

© 2015 Elsevier Ltd. All rights reserved.

PMID: 25903526  [PubMed - in process]

האתר מעודכן נכון לתאריך:  17/07/2017 8:38:26 PM
עבור לתוכן העמוד